Literature DB >> 25203958

Angiogenesis as a therapeutic target in endometriosis.

Dusan Djokovic1, Carlos Calhaz-Jorge2.   

Abstract

INTRODUCTION: Angiogenesis is a key factor for the successful establishment and growth of endometriotic lesions.
MATERIAL AND METHODS: We performed a literature search in PubMed and reviewed the most pertinent studies published until January 2014 and focused on the endometriosis-associated angiogenesis and/or anti-angiogenic strategies for the treatment of this gynecological disorder.
RESULTS: The present review provides a concise summary of the known molecular mechanisms that promote vascularization of endometriotic lesions and may serve as potential therapeutic targets. We also present a systematic overview of the inclusive and exclusive anti-angiogenic agents that have been already studied in cell cultures, animal models and/or endometriosis patients. DISCUSSION AND
CONCLUSION: The integration of anti-angiogenic approaches in the multimodal management strategies for endometriosis patients will be conditioned by the outcomes of future assessments regarding the effectiveness of such treatments, the risk of drug resistance development and the incidence of unacceptable side effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25203958     DOI: 10.20344/amp.5244

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  12 in total

1.  Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice.

Authors:  A R Koippallil Gopalakrishnan; H Pandit; S M Metkari; N Warty; T Madan
Journal:  Gene Ther       Date:  2016-03-18       Impact factor: 5.250

2.  Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signalling suppresses the vascularisation and growth of endometriotic lesions.

Authors:  Jeannette Rudzitis-Auth; Sophia A Fuß; Vivien Becker; Michael D Menger; Matthias W Laschke
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

3.  Antiangiogenic Effect of Ethanol Extract of Vigna angularis via Inhibition of Phosphorylation of VEGFR2, Erk, and Akt.

Authors:  Oh Sung Kwon; Myoung Seok Jeong; Bonglee Kim; Sung-Hoon Kim
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-19       Impact factor: 2.629

4.  The combination of N-acetyl cysteine, alpha-lipoic acid, and bromelain shows high anti-inflammatory properties in novel in vivo and in vitro models of endometriosis.

Authors:  C Agostinis; S Zorzet; R De Leo; G Zauli; F De Seta; R Bulla
Journal:  Mediators Inflamm       Date:  2015-04-16       Impact factor: 4.711

Review 5.  Somatic stem cells and their dysfunction in endometriosis.

Authors:  Dusan Djokovic; Carlos Calhaz-Jorge
Journal:  Front Surg       Date:  2015-01-06

6.  Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway.

Authors:  Yang Cao; Qing Ye; Mengfei Zhuang; Shuwu Xie; Ruihua Zhong; Jingang Cui; Jieyun Zhou; Yan Zhu; Tingting Zhang; Lin Cao
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

7.  Identification of global transcriptome abnormalities and potential biomarkers in eutopic endometria of women with endometriosis: A preliminary study.

Authors:  Luyang Zhao; Chenglei Gu; Mingxia Ye; Zhe Zhang; Weidong Han; Wensheng Fan; Yuanguang Meng
Journal:  Biomed Rep       Date:  2017-05-03

Review 8.  Anti-Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms.

Authors:  Weilin Zheng; Lixing Cao; Zheng Xu; Yuanyuan Ma; Xuefang Liang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-01       Impact factor: 2.629

Review 9.  Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted?

Authors:  David A Hart
Journal:  Int J Inflam       Date:  2015-10-15

10.  Shaofu Zhuyu Decoction Regresses Endometriotic Lesions in a Rat Model.

Authors:  Guanghui Zhu; Chunhua Jiang; Xin Yan; Shu Zhao; Dingjie Xu; Ying Cao
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-30       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.